Symphony Clinical Research? Announces VP Appointment
News Feb 21, 2013
Ms. Zarish is responsible for establishing and implementing the operational objectives and clinical processes employed by the global clinical team to deliver exceptional customer service with an unparalleled commitment to quality. She provides leadership to develop, grow and optimize the capabilities of Study Development, Study Management, Study Support and Document Management functions.
Ms. Zarish comes from Abbott Global Pharmaceutical Research & Development where she led an international team of study managers in the execution of clinical trial operations in multiple therapeutic areas. Kate was instrumental in the harmonization of global processes, tools and training programs for clinical study operations management, as well as standardizing study training for the monitoring staff. She maintains her certification as a Clinical Research Associate from ACRP.
“I am proud to be part of an organization that thinks about the patient first,” said Ms. Zarish. “The high standards we have established for in-home clinical services allows for trained health care professionals to ensure patient safety and to provide data with high integrity. It is the complete package for the patient, site and sponsor.”
Commenting on the new appointment, Nicki Norris, CEO states, “Kate’s role is critical in meeting the explosive demand for in-home clinical services. The pharmaceutical industry worldwide is beginning to realize the importance of reaching the intent-to-treat pool, accommodating debilitated patients, and retaining study participants all while completing trials on time. This is exactly what Symphony’s clinical services provide to our clients.”
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019